Savara (NASDAQ:SVRA) Given “In-Line” Rating at Evercore ISI

Evercore ISI reissued their in-line rating on shares of Savara (NASDAQ:SVRA) in a research note released on Wednesday morning, Marketbeat reports. They currently have a $5.00 target price on the stock, down from their previous target price of $7.00.

Other research analysts also recently issued reports about the stock. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Savara in a research report on Tuesday, October 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Trading Down 15.1 %

SVRA opened at $3.25 on Wednesday. The firm’s 50-day simple moving average is $3.96 and its 200-day simple moving average is $4.22. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a twelve month low of $3.24 and a twelve month high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). As a group, sell-side analysts forecast that Savara will post -0.44 EPS for the current fiscal year.

Institutional Trading of Savara

Institutional investors and hedge funds have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co bought a new stake in Savara during the 1st quarter worth approximately $35,000. Choreo LLC bought a new stake in Savara during the 2nd quarter worth approximately $59,000. DRW Securities LLC bought a new stake in Savara during the 2nd quarter worth approximately $62,000. Principal Financial Group Inc. increased its stake in Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC bought a new stake in Savara during the 2nd quarter worth approximately $105,000. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.